BRANFORD, Conn., Jan. 5 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today that Timothy M. Shannon, M.D., Executive Vice President of Research and Development and Chief Medical Officer at CuraGen, and Christopher K. McLeod, President and Chief Executive Office of 454 Life Sciences, will present at the 24th Annual JPMorgan Healthcare Conference. The presentation will take place at 12:00 p.m. PST (3:00 p.m. EST) on Thursday, January 12, 2006 at the Westin St. Francis Hotel in San Francisco, CA.
The presentation will be webcast live and may be accessed by visiting http://www.curagen.com or http://equityconferences.jpmorgan.com. A replay of the webcast will be available following the presentation and archived for 30 days thereafter.
About CuraGen
CuraGen Corporation is a biopharmaceutical company dedicated to improving the lives of patients by developing a pipeline of novel protein, antibody, and small molecule therapeutics in the areas of oncology, inflammatory diseases, and diabetes. CuraGen has established broad development alliances with Abgenix, TopoTarget, and Bayer, and its experienced preclinical and clinical teams are advancing the Company’s pipeline of products for unmet medical needs. The Company is headquartered in Branford, CT. For additional information please visit http://www.curagen.com.
About 454 Life Sciences
454 Life Sciences, a 66% majority-owned subsidiary of CuraGen Corporation , has developed a novel technology for rapidly and comprehensively conducting high-throughput nucleotide sequencing, with specific application to sequencing of whole genomes and ultra-deep sequencing of target genes. 454 Life Sciences’ Genome Sequencer 20 System enables one individual to prepare and sequence an entire genome after performing a single sample preparation, irrespective of the size of the genome being studied. 454 Life Sciences offers sequencing services directly to customers on a fee for service basis at their state-of-the-art Measurement Services Center. The Genome Sequencer 20 System and reagents are available exclusively from Roche Applied Sciences. For additional information on 454 Life Sciences, please visit http://www.454.com. For additional information on the Genome Sequencer 20 System and reagents, please visit http://www.roche-applied-science.com.
Contact: Glenn Schulman, Pharm.D. Assistant Director of Investor Relations gschulman@curagen.com (888) 436-6642
CuraGen Corporation
CONTACT: Glenn Schulman, Pharm.D., Assistant Director of InvestorRelations of CuraGen Corporation, +1-888-436-6642, gschulman@curagen.com
Web site: http://www.curagen.com//